Source: Eur Respir J 2003; 22: 560-562
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Abramowicz M.J., Van Haecke P., Demedts M., Delcroix M.. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 2003; 22: 560-562

Member's Comments

No comment yet.

Related content which might interest you: BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Source: Eur Respir J 2002; 20: 518-523 Year: 2002 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Pulmonary vascular disease: an historical perspective Source: Eur Respir Mon 2012; 57: 1-16 Year: 2012 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017 Year: 2017 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females Source: Eur Respir J 2009; 34: 1093-1099 Year: 2009 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Outcomes of a phase II study of ACT-293987, an oral IP receptor agonist, in pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pathobiology of pulmonary arterial hypertension and right ventricular failure Source: Eur Respir J 2012; 40: 1555-1565 Year: 2012 Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Source: Eur Respir J 2004; 24: 371-374 Year: 2004 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005